These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 35151584)
1. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Palomba ML; Cartron G; Popplewell L; Ribrag V; Westin J; Huw LY; Agarwal S; Shivhare M; Hong WJ; Raval A; Chang AC; Penuel E; Morschhauser F Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):504-512. PubMed ID: 35151584 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682 [TBL] [Abstract][Full Text] [Related]
3. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study. Palomba ML; Till BG; Park SI; Morschhauser F; Cartron G; Marks R; Shivhare M; Hong WJ; Raval A; Chang AC; Penuel E; Popplewell LL Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e443-e451. PubMed ID: 35031227 [TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746 [TBL] [Abstract][Full Text] [Related]
5. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Sarkozy C; Morschhauser F; Dubois S; Molina T; Michot JM; Cullières-Dartigues P; Suttle B; Karlin L; Le Gouill S; Picquenot JM; Dubois R; Tilly H; Herbaux C; Jardin F; Salles G; Ribrag V Clin Cancer Res; 2020 Jul; 26(13):3145-3153. PubMed ID: 32122924 [TBL] [Abstract][Full Text] [Related]
6. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362 [TBL] [Abstract][Full Text] [Related]
7. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment. Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935 [TBL] [Abstract][Full Text] [Related]
8. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457 [TBL] [Abstract][Full Text] [Related]
9. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma. Carlo-Stella C; Zinzani PL; Sureda A; Araújo L; Casasnovas O; Carpio C; Yeh SP; Bouabdallah K; Cartron G; Kim WS; Cordoba R; Koh Y; Re A; Alves D; Chamuleau M; Le Gouill S; López-Guillermo A; Moreira I; van der Poel MWM; Abbadessa G; Meng R; Ji R; Lépine L; Saleem R; Ribrag V Hematol Oncol; 2023 Feb; 41(1):108-119. PubMed ID: 36251503 [TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457 [TBL] [Abstract][Full Text] [Related]
12. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752 [TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. Julia E; Salles G Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777 [TBL] [Abstract][Full Text] [Related]
14. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434 [TBL] [Abstract][Full Text] [Related]
15. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib. Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216 [TBL] [Abstract][Full Text] [Related]
16. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma. Godfrey J; Mei M; Chen L; Song JY; Bedell V; Budde E; Armenian S; Puverel S; Nikolaenko L; Chen R; Daniels S; Kennedy N; Peters L; Rosen ST; Forman SJ; Popplewell LL; Kwak LW; Herrera AF Haematologica; 2024 Feb; 109(2):533-542. PubMed ID: 37470137 [TBL] [Abstract][Full Text] [Related]
17. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Geoerger B; Zwaan CM; Marshall LV; Michon J; Bourdeaut F; Casanova M; Corradini N; Rossato G; Farid-Kapadia M; Shemesh CS; Hutchinson KE; Donaldson F; Liao M; Caron H; Trippett T Lancet Oncol; 2020 Jan; 21(1):134-144. PubMed ID: 31780255 [TBL] [Abstract][Full Text] [Related]
18. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Roschewski M; Patel MR; Reagan PM; Saba NS; Collins GP; Arkenau HT; de Vos S; Nuttall B; Acar M; Burke K; White RD; Udriste M; Sharma S; Dougherty B; Stetson D; Jenkins D; Mortlock A; Forcina A; Munugalavadla V; Flinn I Clin Cancer Res; 2023 Sep; 29(17):3301-3312. PubMed ID: 37364001 [TBL] [Abstract][Full Text] [Related]
19. A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ribrag V; Lee ST; Rizzieri D; Dyer MJS; Fayad L; Kurzrock R; Andritsos L; Bouabdallah R; Hayat A; Bacon L; Jiang Y; Miah K; Delafont B; Hamid O; Anyanwu S; Martinez P; Hess B Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):309-317.e3. PubMed ID: 33632668 [TBL] [Abstract][Full Text] [Related]